XSUITE
7.8.2024 15:48:31 CEST | Business Wire | Press release
xSuite Nordic, a subsidiary of software manufacturer xSuite Group, invites customers and prospects to its roadshow in Copenhagen/Valby (5.9.24) and Horsens (12.9.24). Participants will be taken on a journey that brings them closer to SAP S/4HANA, Clean Core and the SAP Business Technology Platform (BTP). They will learn how xSuite solutions can be used to set up future-proof P2P processes for SAP S/4HANA. xSuite will also showcase how to combine automation and intuitive workflows for incoming invoice processing based on the clean core principle.
SAP user companies have a lot on their plate these days: Prepare for the migration to S/4HANA, push ahead process digitization and improvement, and move to the cloud. At the roadshow, Bo Bærentsen, Senior Business Consultant, and Michael Francker Christensen, Solution Architect (both from xSuite), will present how xSuite supports organizations on their journey to a clean core, with a focus on P2P processes and SAP S/4HANA.
Maiken Borup-Mikkelsen, People Lead & Director DC, SAP at Deloitte Denmark, talks about the future of work: What does the future of work look like in the SAP context? In Valby, Ólafur Harðarson, IT Application Manager from Síminn Telecommunications Reykjavik Island, will introduce Síminn’s change story “From a lot of SAP to better SAP”.
In Horsens, Charlotte Uhrskov Johansen, Project Lead & Manager Future Finance at Bestseller, will present how the company migrated to S/4HANA globally in order to achieve more automation and efficiency in financial processes. Bestseller is implementing SAP Fiori for all financial processes in the S/4HANA Private Cloud.
Martin Lundsteen, Managing Director of xSuite Nordic, will guide participants through the series of presentations on both dates. Afterwards, xSuite invites guests to a get-together from 12 noon to 1 p.m.
Event information:
Duration of both events: 9:30 a.m. – 1:00 p.m.
The presentations will be given in Danish at both locations.
05.9.24, Copenhagen/Valby
Transformerstationen
Gl. Køge Landevej 18
2500 Valby, Denmark
12.9.24, Horsens
Jorgensens Hotel
Søndergade 17
8700 Horsens, Denmark
More information and registration: https://news.xsuite.com/en/international-roadshow-2024
About xSuite
With offices in Europe, Asia, and the U.S., as well as ample experience across industries and multiple SAP solutions, xSuite is a top innovator in optimizing SAP-based P2P workflows, providing software and implementing solutions for over 1,300 clients. The company has become a trusted partner in modernizing AP systems and automating manual, paper-based processes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807495174/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom